Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | LIPE | Q05469 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6204537 | 0.86 | KDM4E (0.46) | USP30CHRM3GPR119KDM4EPKM | |
| SCHEMBL14560 | 0.80 | LIPE (0.48) | LIPE | |
| SCHEMBL828713 | 0.79 | CHRM3 (0.51) | CHRM3GPR119PTPN2PTPN1PTPN6 | |
| SCHEMBL6682953 | 0.79 | TGFBR1 (0.53) | CHRM3GPR119PTPN2PTPN1PTPN6 | |
| SCHEMBL24906656 | 0.78 | CHRM3 (0.70) | CHRM3 | |
| SCHEMBL13261270 | 0.78 | STS (0.47) | USP30GPR119PTPN2PTPN1PTPN6 | |
| SCHEMBL3376953 | 0.78 | PDE4B (0.47) | USP30GPR119KDM4EPKMKDM1A | |
| SCHEMBL1295885 | 0.77 | KMT2A (0.59) | USP30KDM4E | |
| SCHEMBL12105458 | 0.77 | MEN1 (0.42) | USP30PTPN2PTPN1PTPN6LIPE | |
| SCHEMBL1294831 | 0.77 | KMT2A (0.59) | USP30KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143277-B2 | Method of using compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20090239904-A1 | COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-7569586-B2 | Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| EP-1833822-A2 | COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | Theravance, Inc. (US) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006023460-A2 | COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20060035933-A1 | Compounds having beta adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE BIOPHARMA R&D IP, LLC | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035933-A1 | Compounds having beta adrenergic receptor agonist and muscarinic receptor antagonist activity | ADRA2B, ADRB1, ADRA1B | USP30 3826/4885CHRM3 12/4885GPR119 207/4885 |
| US-20090239904-A1 | COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | ADRA2B, ADRB2, ADRB1 | USP30 4042/4885CHRM3 12/4885GPR119 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.